These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6185438)

  • 1. [Tolerance of a new intravenously applied immunoglobulin preparation and its effect on serum globulin levels].
    Hansi W; Heimpel H; Barandun S; Lutz O
    Infection; 1982; 10(6):347-51. PubMed ID: 6185438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with gammaglobulin preparation for intravenous use in children with humoral immunodeficiency: clinical and immunologic follow-up.
    Galli E; Barbieri C; Cantani A; Solano A; Longhi MA; Businco L
    Ann Allergy; 1990 Feb; 64(2 Pt 1):147-50. PubMed ID: 2106278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutical application of gammaglobulin preparations in inborn immunodeficiency syndromes (author's transl)].
    Mietens C
    Immun Infekt; 1981 Sep; 9(5):170-4. PubMed ID: 6170572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of primary immunodeficiencies with intravenous gamma globulin].
    García Rodríguez C; López Trascasa M; Ferreira Cerdán A; Fontán Casariego G
    An Esp Pediatr; 1987 Dec; 27(6):411-5. PubMed ID: 2451892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and toxicity of a new serum immunoglobulin G intravenous preparation, IGIV pH 4.25.
    Pirofsky B
    Rev Infect Dis; 1986; 8 Suppl 4():S457-63. PubMed ID: 3092311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease.
    Cunningham-Rundles C; Siegal FP; Smithwick EM; Lion-Boulé A; Cunningham-Rundles S; O'Malley J; Barandun S; Good RA
    Ann Intern Med; 1984 Oct; 101(4):435-9. PubMed ID: 6206756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective controlled crossover trial of a new presentation (10% vs. 5%) of a heat-treated intravenous immunoglobulin.
    Matamoros N; De Gracia J; Hernández F; Pons J; Alvarez A; Jiménez V
    Int Immunopharmacol; 2005 Mar; 5(3):619-26. PubMed ID: 15683857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a new chemically modified intravenous IgG preparation in severe primary humoral immunodeficiency: clinical efficacy and attempts to individualize dosage.
    Schiff RI; Rudd C; Johnson R; Buckley RH
    Clin Immunol Immunopathol; 1984 Apr; 31(1):13-23. PubMed ID: 6421523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical results with a new intravenous immunoglobulin preparation (author's transl)].
    Hansi W; Kratzsch G; Heimpel H
    Dtsch Med Wochenschr; 1980 Nov; 105(48):1675-80. PubMed ID: 7439053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.
    Shapiro RS
    Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intravenous immunoglobulin administration for antibody deficiency (author's transl)].
    Luthardt T
    Dtsch Med Wochenschr; 1980 Jul; 105(28):993-7. PubMed ID: 7408694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gamma globulin in secondary antibody deficiency syndrome].
    Hartwich G
    Fortschr Med; 1979 Oct; 97(39):(1764-6). PubMed ID: 92444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
    Berger M; Murphy E; Riley P; Bergman GE;
    South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody against the human immunodeficiency virus in commercial intravenous gammaglobulin preparations.
    Wood CC; Williams AE; McNamara JG; Annunziata JA; Feorino PM; Conway CO
    Ann Intern Med; 1986 Oct; 105(4):536-8. PubMed ID: 2428274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.
    Jolles S; Sleasman JW
    Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of a new pH 4.25 intravenous immunoglobulin preparation (gamimune-N).
    Pirofsky B
    J Infect; 1987 Jul; 15 Suppl 1():29-37. PubMed ID: 3117898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.
    Stein MR; Nelson RP; Church JA; Wasserman RL; Borte M; Vermylen C; Bichler J;
    J Clin Immunol; 2009 Jan; 29(1):137-44. PubMed ID: 18814020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
    Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
    Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic and hematologic changes occurring after rapid intravenous infusion of gammaglobulin in patients with antibody deficiency syndromes.
    Costa-Carvalho BT; Lin M; Solé D; Carneiro-Sampaio MM; Sorensen RU; Naspitz CK
    Sao Paulo Med J; 1998; 116(5):1815-20. PubMed ID: 10030107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antibody deficiency states in children].
    Mietens C; Bernhard A
    Dtsch Med Wochenschr; 1975 Mar; 100(10):455-60. PubMed ID: 46196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.